

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
December 2019

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (known as Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below is a summary of performance submitted by UCLH in Quarter 3 (2019/20) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of December 2019.

For Further information on PID reporting, please visit the NIHR pages at:

<https://www.nihr.ac.uk/documents/performance-in-initiating-and-delivering-guidelines/19932>

Initiating Clinical Research – HRA Approval

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Benchmark Met	Reasons for delay correspond to:
1	19/NW/0103	257331	MAGNITUDE	15/02/2019	07/07/2019	26/04/2019	06/08/2019	06/08/2019	06/08/2019	21/08/2019	Yes	
2	18/EE/0095	239387	A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer	04/02/2019	17/04/2019	14/05/2018	12/06/2019	12/06/2019	12/06/2019	15/06/2019	No	NHS Provider
3	19/EM/0028	254146	PROTEUS	21/09/2018	01/08/2019	02/04/2019	30/08/2019	30/08/2019	30/08/2019		No	Neither
4	18/EM/0148	236593	Durvalumab + BCG in NMIBC	24/05/2018	15/01/2019			16/01/2019	16/01/2019	27/03/2019	No	Neither
5	19/SC/0172	256280	Elacestrant vs SOC for treatment of ER+/HER2- Breast Cancer	18/03/2019	16/05/2019	07/06/2019		14/08/2019	14/08/2019		No	Sponsor
6	19/NW/0070	247463	EMBOL-1	17/07/2019	08/10/2019	14/05/2019		23/10/2019	23/10/2019		No	Sponsor
7	19/LO/0993	254990	Phase 3 study of Nirogacestat in	20/08/2018	06/08/2019	26/07/2019		11/09/2019	11/09/2019		No	Neither

			Adults with Desmoid Tumor (DT/AF)									
8	19/LO/0255	251219	Little Journey multi-centre randomised controlled trial	17/05/2019	04/09/2019	08/05/2019	05/09/2019	05/09/2019	05/09/2019	20/11/2019	No	Neither
9	18/LO/2102	255753	innovaTV 205	01/11/2019	24/12/2019	29/08/2019	18/09/2019	18/09/2019	18/09/2019		NA	
10	18/SC/0634	233709	STELLAR	05/03/2019	30/08/2019			18/03/2019	18/03/2019	01/07/2019	No	Neither
11	18/WM/0022	237623	AG-348 in Regularly Transfused Adult Subjects with PK Deficiency	02/02/2018	09/01/2019	11/04/2018	03/09/2019	05/12/2019	05/12/2019		No	Neither
12	19/LO/1024	263894	Pembrolizumab ± SBRT in Medically Inoperable Stage I/IIA NSCLC	17/12/2018	03/09/2019	26/07/2019		09/09/2019	09/09/2019	21/11/2019	No	Sponsor
13	16/LO/2067	209688	OPTIMISE II	19/01/2019	18/04/2019	06/01/2017	22/03/2019	28/03/2019	28/03/2019		No	Both
14	18/NW/0713	249575	DIONE – Efficacy and Safety of TD-1473 in Crohn’s Disease	27/07/2018	30/01/2019	28/11/2018		09/12/2019	09/12/2019		No	Both

15	19/SC/0206	259180	Phase 3 extension trial of Glepaglutide in patients with SBS.	03/07/2019	12/08/2019	21/06/2019		20/08/2019	20/08/2019	27/08/2019	No	NHS Provider
16	19/NW/0169	245465	Assessment of Nightingale Monitors in Healthy Volunteers	15/03/2019	15/08/2019	14/09/2019					NA	
17	19/NE/0325	272289	BMR307-201	23/10/2019	04/12/2019	20/12/2019					NA	
18	18/LO/2136	251414	BN40423 Generation HD 1	11/12/2018	22/05/2019	22/02/2019		23/07/2019	31/07/2019	06/08/2019	No	Neither
19	19/LO/1215	261663	ACE-536-LTFU-001	16/08/2019	02/12/2019	04/11/2019					NA	
20	18/SS/0125	237740	PIBCAP	18/12/2018	23/04/2019	14/12/2018	04/09/2019	04/09/2019	04/09/2019		No	Both
21	19/LO/1129	251167	ReIMAGINE Prostate Cancer Screening	25/06/2019	04/10/2019	07/08/2019		17/10/2019	17/10/2019	01/11/2019	Yes	
22	19/LO/0819	263201	A Phase 1b Open Label Study of REN001 in McArdle Disease	26/04/2019	28/08/2019	27/06/2019		22/10/2019	18/11/2019		No	Neither
23	19/NE/0145	254931	FaR-RMS	22/07/2019	18/11/2019	22/07/2019					NA	

24	19/LO/1555	226639	Personalised provision of orthodontic treatment information: Version 1	05/11/2019	05/11/2019	05/11/2019					NA	
25	19/LO/0518	254503	VESTIGE (EORTC 1707-GITCG)	30/04/2019	14/10/2019	16/07/2019					No	NHS Provider
26	18/LO/0106	170254	HYPATIA study	27/02/2018	19/11/2019	09/03/2018		13/12/2019	13/12/2019		No	Neither
27	19/NE/0238	261118	REDUCE (EORTC 1762-STBSG)	17/07/2019	10/09/2019	19/08/2019		10/12/2019	10/12/2019		No	NHS Provider
28	19/LO/1568	266757	Melflufen and Dexamethasone for Patients with AL Amyloidosis	30/09/2019	30/09/2019	02/12/2019					No	Sponsor
29	18/LO/0569	233097	The HOME Study	08/05/2018	25/04/2019			25/04/2019	25/04/2019	18/07/2019	No	Neither
30	18/SC/0614	251365	PTG-300 in NTD and TD β -Thalassaemia patients with Chronic Anaemia	26/09/2018	24/09/2019	17/12/2019					No	Sponsor

31	19/EM/0034	255895	Padsenovil for Focal Seizures in Adults with Drug-Resistant Epilepsy	25/01/2019	12/07/2019	16/06/2019		14/10/2019	05/12/2019		No	Neither
32	19/LO/0421	259113	ROZANOLIXIZUMAB in subjects with CIDP	13/03/2019	07/10/2019		08/11/2019	19/12/2019			No	Sponsor
33	18/LO/1922	251251	Study to Evaluate the Effect of GBT440 in Pediatrics with Sickle Cell	21/02/2019	21/02/2019	09/01/2019	12/03/2019	16/04/2019	16/04/2019	23/04/2019	Yes	
34	18/LO/1882	253030	Abiraterone Acetate + Prednisone with Abemaciclib or placebo for mCRPC	26/11/2018	02/04/2019	13/02/2019	10/04/2019	10/04/2019	10/04/2019	11/06/2019	Yes	
35	17/LO/2088	211212	MS-OPT Study: Simvastatin in Secondary Progressive Multiple Sclerosis	16/03/2018	20/02/2019	31/01/2018		27/03/2019	16/05/2019	19/06/2019	No	NHS Provider
36	19/LO/0359	253287	PK/PD of RO7234292 in CSF and plasma and safety and tolerability in HD	28/01/2019	09/07/2019	10/06/2019	08/02/2019	11/07/2019	11/07/2019	13/08/2019	Yes	
37	19/LO/1152	265415	FIGHT-207	09/07/2019	20/09/2019						No	Sponsor

38	18/LO/1435	247443	ATX-NS-001 - ATL001 for the Treatment of Non-Small Cell Lung Cancer	01/02/2019	01/03/2019	15/02/2019		17/05/2019	05/07/2019	27/08/2019	No	Neither
39	18/LO/2079	243905	Role of AHT#1 food supplement in symptom control of IBS-D	16/02/2018	26/06/2019	29/03/2019	11/07/2019	11/07/2019	11/07/2019	10/10/2019	No	Neither
40	18/WA/0335	240606	PITSTOP	18/09/2018	05/03/2019	01/11/2019		17/05/2019	17/05/2019	02/10/2019	No	Both
41	18/EE/0330	249125	EASE SBS1 Efficacy And Safety Evaluation of Glepaglutide in SBS	21/12/2018	11/02/2019	11/12/2018	21/02/2019	25/04/2019	25/04/2019	16/05/2019	No	NHS Provider
42	17/LO/0980	219505	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	26/11/2018	12/04/2019	10/07/2017	19/06/2019	19/06/2019	19/06/2019	02/12/2019	No	Both
43	18/WA/0239	243333	DELIVER MS	04/12/2018	22/01/2019	21/12/2018		08/03/2019	08/03/2019	25/06/2019	No	Both
44	18/LO/1405	63284	Cochleostomy vs Round Window for Hearing Preservation in CI	13/09/2018	01/04/2019	13/09/2018		02/05/2019	02/05/2019	16/05/2019	Yes	
45	18/LO/0266	235855	Novel multimodality imaging for navigation in skull base surgery	09/04/2018	15/04/2019	09/04/2018	17/04/2019	17/04/2019	17/04/2019	03/06/2019	Yes	

46	18/LO/1918	252958	A Phase 1 Study of BIVV009 in Patients with Chronic ITP (BIVV009-201)	13/08/2018	08/03/2019	08/03/2019		25/03/2019	25/03/2019	24/07/2019	No	Neither
47	19/LO/0101	258992	Cancer Peptide Vaccine	17/12/2018	22/01/2019	02/05/2019	22/01/2019	22/01/2019	05/06/2019	15/07/2019	No	Sponsor
48	16/LO/1656	197553	Natural history and biomarkers in autonomic disorders	22/02/2016	30/10/2019	09/12/2016		01/11/2019	01/11/2019		NA	
49	18/SW/0247	248334	BEGONIA - Phase II study of oncology combinations in 1L Stage IV TNBC.	12/09/2018	12/04/2019			12/04/2019	18/06/2019		No	Neither
50	17/LO/0357	202353	Better Conversations with Primary Progressive Aphasia (BCPPA)	02/11/2016	13/02/2019	26/04/2017	27/03/2019	27/03/2019	27/03/2019	03/05/2019	No	Neither
51	18/LO/1889	250623	TACTI-002 (P015); Keynote-PN798 (Two ACTIVE Immunotherapeutics)	17/10/2018	28/05/2019	12/02/2019	04/07/2019	04/07/2019	15/07/2019	10/10/2019	No	Neither
52	18/EE/0242	245484	Surrogate of Adequate Perfusion: Bladder tissue OXYgen monitoring	20/03/2018	28/03/2019	14/03/2019	26/03/2019	29/03/2019	01/04/2019	05/04/2019	Yes	
53	18/EM/0255	237130	Project on EUS- BD	29/10/2018	07/02/2019	09/10/2018		20/02/2019	20/02/2019		No	Neither

University College London Hospitals



NHS Foundation Trust

54	19/WM/0258	248392	NICOFA		19/09/2019						No	Sponsor
55	18/LO/2053	251610	AL001-1	06/12/2018	25/01/2019	24/01/2019		29/03/2019	04/04/2019	05/06/2019	No	Sponsor
56	18/LO/0434	242324	Fabry disease study to determine the safety and efficacy of lucerastat	19/01/2018	17/07/2019			29/11/2019	29/11/2019		No	NHS Provider
57	18/SW/0100	235621	DAFNEplus Cluster Randomised Controlled Trial	14/09/2017	15/05/2019	18/01/2019	30/08/2019	30/08/2019	30/08/2019	17/10/2019	No	NHS Provider
58	18/LO/1353	238135	Treatment of Urinary Retention with the Axonics SNM system / Version 1	20/07/2018	28/02/2019	09/01/2019		01/03/2019	28/02/2019	14/03/2019	Yes	
59	18/ES/0136	249697	X-linked Hypophosphatemia (XLH) - Kyowa Kirin - 0978/0008	17/12/2018	18/04/2019	21/12/2018	23/05/2019	30/05/2019	30/05/2019	06/08/2019	No	Sponsor
60	19/SC/0094	240646	OPTIC TRIAL	29/01/2018	17/07/2019	16/05/2019	09/10/2019	08/10/2019	08/10/2019	30/10/2019	No	Neither
61	18/LO/0555	237992	PROTECTOR	03/08/2018	29/01/2019	19/04/2018	28/03/2019	28/03/2019	28/03/2019	01/07/2019	No	Sponsor
62	18/LO/2137	244929	PembroWM	09/04/2019	19/06/2019	19/03/2019		20/09/2019	23/09/2019	07/10/2019	No	NHS Provider

63	17/NW/0634	209375	COMICE	05/09/2016	16/05/2019		28/06/2019	28/06/2019	27/08/2019	26/09/2019	No	Neither
64	18/EM/0364	254750	4433: NNC0174-0833 for weight management	03/09/2018	11/01/2019			22/02/2019	22/02/2019	01/03/2019	Yes	
65	19/ES/0049	260196	The ADDapt diet in reducing Crohn's disease inflammation - Version 1	29/04/2019	22/07/2019	15/07/2019	16/08/2019	16/08/2019	16/08/2019	11/09/2019	Yes	
66	18/SC/0610	242511	POPPY	12/11/2018	10/01/2019	08/01/2019		04/04/2019	04/04/2019	07/08/2019	No	Sponsor
67	19/EE/0201	264655	Phase Ib study in Adults with Thalassaemia or Myelodysplastic Syndrome	01/07/2019	12/09/2019						No	Sponsor
68	18/SC/0658	242575	CHOICE - cochlear implant home care	28/11/2018	19/11/2019	28/11/2018	03/12/2019	05/12/2019	05/12/2019		NA	
69	19/YH/0244	263626	Intelligent Operating Room (InOR) for Orthopaedic Surgery	09/07/2019	16/09/2019	06/08/2019		04/10/2019	04/10/2019	07/10/2019	Yes	

70	19/LO/0051	251111	CINOVA	28/01/2019	02/08/2019	18/03/2019	10/10/2019	24/09/2019	24/09/2019		No	Neither
71	18/EM/0085	208868	HOVON 127 BL	27/07/2018	09/09/2019	12/06/2018					No	NHS Provider
72	19/LO/1057	261202	Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC	05/07/2019	06/09/2019	28/08/2019					No	Sponsor
73	19/SC/0021	249552	OPTIMAS Trial	19/12/2018	16/04/2019	04/04/2019	18/06/2019	18/06/2019	18/06/2019	05/07/2019	No	Sponsor
74	19/LO/0452	250324	CASTLE TRIAL v1.0	28/02/2019	13/05/2019	24/06/2019		29/08/2019	29/08/2019		No	Neither
75	19/YH/0094	256470	Protocol 18-513 Andexanet ICH	04/03/2019	19/06/2019	19/06/2019		11/12/2019	11/12/2019		No	NHS Provider
76	19/NE/0031	258311	Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC (KEYNOTE-630)	16/01/2019	04/04/2019	04/03/2019	23/09/2019	23/09/2019	23/09/2019		No	Sponsor
77	19/LO/0109	257158	BN40955 OLE study to evaluate the safety & tolerability of RO7234292	19/12/2018	16/01/2019	07/03/2019	24/05/2019	24/05/2019	24/05/2019	29/05/2019	No	NHS Provider

78	18/LO/1289	245746	M13-494 (Canova): Phase 3 t(11;14)- positive R/R Multiple Myeloma	05/04/2018	24/06/2019	05/09/2018		11/10/2019	11/10/2019	07/11/2019	No	NHS Provider
79	17/LO/2025	229356	ROLo	03/09/2018	12/06/2019	26/04/2018	18/09/2019	18/09/2019	18/09/2019		No	Sponsor
80	18/LO/1383	246037	JCAR017-BCM-003 (0451/0311) TRANSFORM	02/11/2018	22/05/2019	05/12/2018		04/10/2019	10/10/2019	21/10/2019	No	NHS Provider
81	19/LO/0579	251741	Sonic Sleeve (v 0.1)	07/05/2019	14/06/2019	05/06/2019		08/07/2019	08/07/2019	08/08/2019	Yes	
82	19/NW/0317	262846	TR12 Ph 2 Study in Idiopathic Pulmonary Fibrosis-Nalbuphine ER Tablets	16/07/2019	17/09/2019	12/07/2019	29/10/2019	26/11/2019	26/11/2019	27/12/2019	No	Neither
83	18/SS/0085	243640	Alpha-2 agonists for sedation (A2B Trial)	31/01/2019	04/06/2019	14/12/2018		23/10/2019	23/10/2019	14/11/2019	No	Sponsor
84	18/LO/1502	246324	CARRIER-trial: S. aureus decolonization in HPN patients	03/05/2018	25/05/2019	17/12/2018	01/07/2019	01/07/2019	01/07/2019	10/12/2019	No	Neither
85	19/NW/0167	256857	Maternal PKU	08/03/2019	26/06/2019	21/05/2019	05/09/2019	05/09/2019	05/09/2019	11/09/2019	No	Sponsor
86	18/LO/1805	246414	JAVELIN BRCA/ATM	28/01/2019	05/03/2019	19/02/2019					NA	

87	18/EE/0352	238983	Biomarker-Directed, Pembrolizumab Based Combination Therapy for Advanced NSCLC	12/10/2018	19/02/2019	14/02/2018		02/05/2019	02/05/2019		No	Sponsor
88	19/EM/0020	252705	TAPER	30/04/2019	12/11/2019	23/05/2019		10/12/2019	10/12/2019		NA	
89	19/NE/0137	258746	AG-348-C-011 - Extension Study of AG-348 in Adult Subjects with PKD	29/04/2019	16/08/2019	12/06/2019					No	Neither
90	19/NW/0504	264255	Multiple System Atrophy-3965/0014-Biohaven	30/07/2019	12/08/2019	00/01/1900					No	Sponsor
91	19/EE/0168	262098	MK7902-011	01/02/2019	15/08/2019	16/07/2019		01/10/2019	05/11/2019		No	Neither
92	18/LO/1471	248645	AUDIBLE-S	01/08/2018	27/02/2019	14/11/2018	05/03/2019	11/03/2019	11/03/2019		No	Neither
93	19/LO/0516	239383	Assessment of Faecal Incontinence with MAPLe		08/10/2019	12/04/2019	17/12/2019	17/12/2019	17/12/2019		No	NHS Provider
94	19/LO/0296	257867	BIA-2093-213	24/12/2018	05/08/2019	05/08/2019		18/10/2019	18/10/2019		No	Neither
95	19/LO/1360	255855	BE-COLDPLAY	14/03/2019	30/09/2019	30/09/2019		24/10/2019	24/10/2019	05/11/2019	Yes	
96	19/LO/0911	263607	Research Using an Investigational Treatment for CNM	16/05/2019	04/09/2019	08/08/2019		17/12/2019	17/12/2019		No	NHS Provider

			(Unite-CNM)									
97	19/NE/0174	264235	PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) RN5609C00	30/04/2019	22/06/2019	24/07/2019		18/12/2019	06/01/2020		No	Sponsor
98	18/WA/0108	235402	ICONS II: Identifying Continence Options after Stroke	12/11/2018	10/06/2019	30/11/2018		04/09/2019	04/09/2019	17/12/2019	No	NHS Provider
99	19/NW/0413	261821	PATTERN	24/06/2019	27/08/2019	27/08/2019		11/12/2019	11/12/2019		No	NHS Provider
100	19/LO/1270	261294	Cerclage after full dilatation caesarean section	16/08/2019	08/10/2019	11/09/2019	27/11/2019	04/12/2019	05/12/2019	11/12/2019	Yes	
101	19/LO/0111	256040	Open Label Extension study (OLE) of the Modify study	09/01/2019	20/05/2019	18/03/2019					No	NHS Provider
102	18/LO/1937	249639	Eribulin mesilate with irinotecan in children with solid tumours	26/10/2018	14/05/2019	01/03/2019					No	NHS Provider
103	18/NW/0269	241839	Safety & Efficacy of Padsevonil in Subjects With DrugResistant Epilepsy	29/03/2019	01/05/2019	28/09/2018					No	NHS Provider
104	18/LO/0368	235386	NICO	13/04/2018	17/04/2019	18/05/2018					No	NHS Provider

105	18/WA/0412	253082	EMPOWER Cervical 1	20/06/2019	17/09/2019	05/09/2019		22/11/2019	25/11/2019		No	NHS Provider
106	19/LO/1134	264080	Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTD	23/02/2019	15/04/2019	18/11/2019		13/12/2019	29/12/2019		No	Neither
107	19/NW/0445	267012	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy	28/08/2019	04/12/2019	20/08/2019		04/12/2019			NA	
108	18/SC/0497	251148	AGI-134		22/01/2019	28/01/2019					No	NHS Provider
109	19/LO/0870	252908	ToTem	15/02/2019	18/06/2019	08/07/2019	07/10/2019	07/10/2019	07/10/2019	20/12/2019	No	Neither
110	17/NW/0581	214739	SC IL-1Ra in SAH - phase III trial	04/05/2018	05/03/2019	07/08/2018		26/07/2019	26/07/2019	07/11/2019	No	Both

111	18/EM/0184	233744	Desmopressin for treatment of stroke patients on antiplatelet therapy	21/09/2018	22/07/2019	04/09/2018		02/08/2019	02/08/2019		No	Sponsor
112	18/YH/0473	252065	BLOC-ICH - BLOcking the Cytokine IL-1 in ICH	09/11/2018	17/04/2019	25/01/2019	11/09/2019	17/09/2019	17/09/2019		No	Both
113	18/EM/0390	251145	Open-Label Study of M281 in Pregnant Women at High Risk for HDFN	11/04/2018	28/08/2019	11/01/2019		06/12/2019	06/12/2019		No	NHS Provider
114	19/YH/0247	266732	4451-STEP TEENS-semaglutide effect in adolescents with obesity	24/07/2019	04/10/2019	25/09/2019	26/11/2019	29/11/2019	05/12/2019	11/12/2019	No	Sponsor
115	19/LO/0124	251868	ASP8374 alone and with pembrolizumab for advanced solid tumours	04/01/2019	04/01/2019	24/04/2019	30/08/2019	30/08/2019	09/09/2019	05/09/2019	No	Sponsor
116	19/EM/0063	253607	AMADEUS	18/04/2019	19/09/2019	14/05/2019	25/09/2019	25/09/2019	30/09/2019	14/11/2019	Yes	
117	19/LO/0204	254814	PERCEPT - myeloma transplant prehab study	14/12/2018	09/05/2019	26/03/2019	23/05/2019	24/05/2019	24/05/2019	05/06/2019	Yes	

Delivering Clinical Research

#	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
1	16/LO/2008	208047	Phase I/II study evaluating AUTO2 in patients with multiple myeloma	Number Agreed	10	10	Date Agreed	30/09/2019	9	05/09/2019	9	Withdrawn By Sponsor	
2	16/LO/1466	210027	PRX-102 compared to Agalsidase Beta for the treatment of Fabry Disease	Number Agreed	1	1	Date Agreed	31/05/2017	0	30/09/2019	0	Recruitment Finished	This trial was terminated without UCLH screening or recruiting any patients

3	16/LO/1701	198559	A Phase 1b (Open Label) / Phase 2 (Randomized Double-Blinded) Study Evaluating the Efficacy of Gemcitabine and Docetaxel With or Without a Human Anti-PDGFRa Monoclonal Antibody (Olaratumab) in the Treatment of Advanced Soft Tissue Sarcoma	Number Agreed	1	1	Date Agreed	31/05/2018	1	20/05/2019	1	Recruitment Finished
4	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study)	Number Agreed	2	2	Date Agreed	30/11/2018	1	30/04/2019	1	Withdrawn By Sponsor
5	16/LO/0985	202286	CHECKpoint pathway and nivolumAb clinical Trial Evaluation 577	Number Agreed	2	2	Date Agreed	30/06/2019	0	09/08/2019	0	Recruitment Finished

6	17/LO/1367	225049	MO29872: Atezolizumab compared with chemotherapy in NSCLC	Number Agreed	6	6	Date Agreed	31/10/2019	11	23/09/2019	11	Recruitm ent Finished	Study now in follow-up
7	17/EE/0080	220727	ARTIST 1	Number Agreed	5	5	Date Agreed	28/02/2019	0	24/06/2019	0	Recruitm ent Finished	Recruitme nt terminate d early. Global Competiti ve Recruitme nt Target Met.
8	17/LO/1306	228268	REACH 3	Number Agreed	2	2	Date Agreed	31/12/2018	10	07/11/2019	10	Recruitm ent Finished	
9	17/LO/1930	235819	A Study of the Safety of IV Brincidofovir for Adenovirus Infection	Number Agreed	2	2	Date Agreed	07/02/2019	0	20/05/2019	6	Recruitm ent Finished	
10	17/EM/0438	232094	A Phase 2 study of Luspatercept vs Placebo in Beta Thalassaemia	Number Agreed	1	1	Date Agreed	28/02/2019	3	14/10/2019	5	Recruitm ent Finished	UCLH exceeded recruitme nt target. Study now in follow-up.

11	17/LO/2060	230779	ZUMA-7	Number Agreed	5	5	Date Agreed	30/11/2019	2	23/09/2019	2	Recruitment Finished	
	18/WS/0137	247036	VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC	Number Agreed	10	10	Date Agreed	22/08/2019	2	22/08/2019	2	Recruitment Finished	Study now in follow-up
	18/EE/0352	238983	Biomarker-Directed, Pembrolizumab Based Combination Therapy for Advanced NSCLC	Range Agreed	4	6	Date Agreed	30/03/2020	0	28/10/2019	0	Withdrawn By Sponsor	Standard of care has changed so patients are no longer deriving benefit by going onto this study. Agreed by sponsor and UCLH that trial should be abandoned at UCLH.
	17/LO/0741	216587	MOVES-PD	Number Agreed	5	5	Not Available / Not Agreed			31/10/2019	3	Recruitment Finished	

18/LO/1313	246934	Ph3 Randomised Double-blind Study of Arimoclomol in Patients with ALS	Number Agreed	10	10	Date Agreed	31/05/2019	3	30/05/2019	4	Recruitment Finished	Study now in follow-up
18/SW/0023	238640	228PD201 Phase 2a study testing BIIB054 for Parkinson's Disease	Number Agreed	4	4	Date Agreed	29/02/2020	1	19/04/2019	1	Recruitment Finished	
18/EM/0364	254750	4433: NNC0174-0833 for weight management	Number Agreed	8	8	Date Agreed	16/08/2019	12	13/08/2019	12	Recruitment Finished	Study now in follow-up
18/LO/0416	235395	Evaluation of Avelumab combined with Talazoparib in solid tumours	Number Agreed	15	15	Date Agreed	31/03/2020	1	15/11/2019	1	Recruitment Finished	